Atuveciclib

DB20084InvestigationalSmall molecule

Atuveciclib is a small molecule drug. The usage of the INN stem '-ciclib' in the name indicates that Atuveciclib is a cyclin dependant kinase inhibitor. Atuveciclib is under investigation in... Atuveciclib is under investigation in clinical trial NCT02345382 (Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia).

Mechanism: Pharmacologically active on Cyclin-dependent kinase 9
Curator reviewed
Formula / weight: C₁₈H₁₈FN₅O₂S · 387.43 g/mol (avg)

Resolves to

Compound

UNII63Q7F59W0VCAS1414943-94-4ChEMBLCHEMBL4439321ChEBI757673PubChem121488167

Structure

InChIKeyACWKGTGIJRCOOM-HHHXNRCGSA-NSMILESCOC1=C(C=CC(F)=C1)C1=NC(NC2=CC(C[S@](C)(=N)=O)=CC=C2)=NC=N1

Targets

P50750CDK9

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Atuveciclib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account